Global Study iLEADS Launches in Argentina to Tackle Early-Onset Alzheimer’s
A new international study, iLEADS (International Longitudinal Early Onset Alzheimer Study), has launched in Argentina with the participation of the Fleni Foundation, aiming to investigate Alzheimer’s disease in individuals under 65 years of age. This initiative marks a crucial step in understanding and addressing a form of the disease often overlooked in traditional research.
Understanding Early-Onset Alzheimer’s
Alzheimer’s disease doesn’t begin with the appearance of symptoms in older adulthood. the pathological processes start much earlier, often between the ages of 45, and 50. This understanding is vital, particularly in societies with increasing life expectancies, according to Dr. Ricardo Allegri, head of the Cognitive Neurology, Neuropsychology and Neuropsychiatry Service at Fleni [Infobae].
The iLEADS Study: Goals and Objectives
The primary goal of the iLEADS study is to analyze cases of Alzheimer’s in younger individuals, identify genetic determinants and early biomarkers, and monitor the progression of the disease. Researchers aim to develop clinical measures and biomarkers for apply in both clinical practice and future research. The study seeks to pave the way for therapies that can slow or halt the disease’s progression and establish collaborative networks with specialized institutions to facilitate clinical trials [Infobae].
Why Focus on Early Onset?
Early-onset Alzheimer’s, while representing only around 5% of symptomatic cases in the United States, can be more aggressive and often goes undiagnosed [Archyde]. Misdiagnosis is common, and patients are frequently excluded from research studies due to age or atypical presentation. Dr. Allegri emphasizes the need to analyze what happens before the age of 65 and intervene proactively.
International Collaboration and Expertise
The iLEADS study, initiated in the USA in 2018 under the direction of Dr. Liana Apostolova of Indiana University, currently includes approximately 850 participants with cognitive impairment and 100 cognitively healthy individuals aged 40-64, distributed across 18 American centers. Funding comes from the United States National Institutes of Health (NIH) and the Alzheimer Association [Archyde]. In 2025, centers in England, Spain, and the Netherlands joined the study, and Fleni in Argentina is the first center in Latin America to participate.
Dr. María Carrillo, scientific director of the Alzheimer Association of the United States, played a key role in expanding the study to Argentina, recognizing the importance of incorporating diverse patient profiles into the research.
The Importance of Prevention and Lifestyle Factors
Experts highlight the growing prevalence of Alzheimer’s disease, linked to increased life expectancy. Controlling risk factors like high blood pressure, diabetes, and cholesterol, alongside lifestyle choices such as diet, exercise, and cognitive stimulation, are crucial for prevention. Studies suggest that up to 60% of dementia cases in Argentina could be preventable through addressing these factors [Infobae].
The LatAm-FINGERS study, the first non-pharmacological study in Latin America, is investigating whether modifying lifestyle habits can have a comparable impact to interventions seen in Finland and the United States.
Looking Ahead
Researchers envision a future of personalized Alzheimer’s management, tailored to the specific risk factor profiles of different populations. The iLEADS study, by incorporating more countries and diverse patient populations, aims to contribute to the development of adapted treatments and ultimately intervene earlier in the disease process.